New research collaboration will explore the differentiation of eblasakimab's mechanism of action versus biologic therapies for atopic dermatitis (AD), dupilumab and lebrikizumab. The findings will ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window We were like ...

In a retrospective review of 184 children with atopic dermatitis (AD) treated with dupilumab, four of the 19 who received live-attenuated vaccines experienced adverse events, including one ...

A retrospective analysis finds no adverse events (AEs) in children receiving a live attenuated vaccine against measles, mumps, rubella, and varicella (MMRV) while on dupilumab or methotrexate ...